ATRT–SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance

Federico, Aniello ; Thomas, Christian

; Miskiewicz, Katarzyna ; Woltering, Niklas

; Zin, Francesca ; Nemes, Karolina ; Bison, Brigitte ; Johann, Pascal D. ; Hawes, Debra ; Bens, Susanne ; Kordes, Uwe ; Albrecht, Steffen ; Dohmen, Hildegard ; Hauser, Peter ; Keyvani, Kathy ; van Landeghem, Frank K. H.

; Lund, Eva Løbner ; Scheie, David ; Mawrin, Christian ; Monoranu, Camelia-Maria ; Parm Ulhøi, Benedicte ; Pietsch, Torsten ; Reinhard, Harald ; Riemenschneider, Markus J. ; Sehested, Astrid ; Sumerauer, David ; Siebert, Reiner ; Paulus, Werner ; Frühwald, Michael C. ; Kool, Marcel ; Hasselblatt, Martin

Alternative links to fulltext:DOI Publisher

Details

Indexed in

Export bibliographical data

Abstract

Abstract

Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive central nervous system tumor characterized by loss of SMARCB1/INI1 protein expression and comprises three distinct molecular groups, ATRT-TYR, ATRT-MYC and ATRT-SHH. ATRT-SHH represents the largest molecular group and is heterogeneous with regard to age, tumor location and epigenetic profile. We, therefore, aimed to investigate if heterogeneity within ATRT-SHH might also have biological and clinical importance. Consensus clustering of DNA methylation profiles and confirmatory t-SNE analysis of 65 ATRT-SHH yielded three robust molecular subgroups, i.e., SHH-1A, SHH-1B and SHH-2. These subgroups differed by median age of onset (SHH-1A: 18 months, SHH-1B: 107 months, SHH-2: 13 months) and tumor location (SHH-1A: 88% supratentorial; SHH-1B: 85% supratentorial; SHH-2: 93% infratentorial, often extending to the pineal region). Subgroups showed comparable SMARCB1 mutational profiles, but pathogenic/likely pathogenic SMARCB1 germline variants were over-represented in SHH-2 (63%) as compared to SHH-1A (20%) and SHH-1B (0%). Protein expression of proneural marker ASCL1 (enriched in SHH-1B) and glial markers OLIG2 and GFAP (absent in SHH-2) as well as global mRNA expression patterns differed, but all subgroups were characterized by overexpression of SHH as well as Notch pathway members. In a Drosophila model, knockdown of Snr1 (the fly homologue of SMARCB1) in hedgehog activated cells not only altered hedgehog signaling, but also caused aberrant Notch signaling and formation of tumor-like structures. Finally, on survival analysis, molecular subgroup and age of onset (but not ASCL1 staining status) were independently associated with overall survival, older patients (> 3 years) harboring SHH-1B experiencing relatively favorable outcome. In conclusion, ATRT-SHH comprises three subgroups characterized by SHH and Notch pathway activation, but divergent molecular and clinical features. Our data suggest that molecular subgrouping of ATRT-SHH has prognostic relevance and might aid to stratify patients within future clinical trials.

Owner only: item control page

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

Details

Indexed in

Export bibliographical data

Abstract

Abstract

Alternative Statistics (altmetrics)

More literature (via CORE)

University Library